menu

Establishing a Diagnosis in Cushing’s Syndrome: An Individualized Approach

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Optimizing Outcomes of Cushing’s Disease Through Strategic Screening, Early Diagnosis, and Timely Treatment

Establishing a Diagnosis in Cushing’s Syndrome: An Individualized Approach

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Related
Comments
  • Overview

    Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Maria Fleseriu, MD, FACE
    Professor of Medicine and Neurological Surgery
    Director, Pituitary Center
    Oregon Health & Science University
    Portland, OR

    Dr. Fleseriu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Crinetics, Recordati, Sparrow
    Research: Crinetics, Recordati, Sparrow, Xeris

    Faculty:
    Richard J. Auchus, MD
    The James A. Shayman and Andrea S. Kervick Professor of Translational Medicine
    Department of Pharmacology and Internal Medicine
    University of Michigan
    Ann Arbor, MI

    Dr. Auchus has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Corcept Therapeutics, Crinetics, Recordati, Sparrow, Xeris
    Research: Corcept Therapeutics, Crinetics, Recordati, Sparrow, Xeris

    Martin Reincke, MD
    Director, Department of Medicine IV
    Ludwig-Maximilians University
    Munich, Germany

    Dr. Reincke has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Crinetics, HRA Pharma, Lundbeck, Recordati

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Mara Siegel has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Select patients who may benefit from screening for Cushing’s disease (CD) based on current guidelines
    • Summarize new data on CD recurrence including the growing role of medical therapy in persistent and recurrent CD and in those who are not surgical candidates
    • Apply data from recent clinical trials and evidence-based guidelines in order to tailor medical therapy using factors such as disease severity and comorbidities
    • Communicate effectively with patients about the efficacy and safety of medical therapies for CD and properly monitor and manage adverse effects
  • Target Audience

    This activity is designed to meet the educational needs of endocrinologists, primary care physicians, and advanced practice providers. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until January 25, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hours/0.1 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-24-004-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Recordati Rare Diseases.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 May 2024